Clarissa Desjardins
Director/Board Member at BELLUS HEALTH
Net worth: 568 374 $ as of 2024-03-30
Profile
Clarissa Desjardins founded Caprion Pharmaceuticals, Inc. in 1998, where she worked as Director & Senior VP-Corporate Development from 1998 to 2007, Advanced Bioconcept Ltd.
in 1992, where she worked as Vice President-Business Development from 1992 to 1998, Clementia Pharmaceuticals, Inc. in 2011, where she worked as President, Chief Executive Officer & Director from 2011 to 2019, and Congruence Therapeutics, Inc. in 2021, where she is working as Chief Executive Officer.
Dr. Desjardins also currently works at Insmed, Inc., as Independent Director from 2019, BELLUS Health, Inc., as Director from 2017, and Insitut de Recherche en Immunologie et en Cancérologie, as Director.
Dr. Desjardins also formerly worked at Cepmed, as President, Chief Executive Officer & Director from 2009 to 2012, Xenon Pharmaceuticals, Inc., as Independent Director, Genome Canada, as Director, and La Fondation de l'innovation du Nouveau-Brunswick, as Director.
Dr. Desjardins received her undergraduate degree in 1992 from McGill University and doctorate degree from McGill University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
INSMED INCORPORATED
0.01% | 2023-05-10 | 20,950 ( 0.01% ) | 568 374 $ | 2024-03-30 |
Clarissa Desjardins active positions
| Companies | Position | Start |
|---|---|---|
| BELLUS HEALTH | Director/Board Member | 2017-09-26 |
| INSMED INCORPORATED | Director/Board Member | 2019-10-31 |
Congruence Therapeutics, Inc.
 Congruence Therapeutics, Inc. BiotechnologyHealth Technology Congruence Therapeutics, Inc. is a Canadian biotechnology company that operates in the field of medicine. The company was founded in 2021 by Clarissa Desjardins. Clarissa Desjardins has been the CEO since 2021. | Chief Executive Officer | - |
Insitut de Recherche en Immunologie et en Cancérologie
 Insitut de Recherche en Immunologie et en Cancérologie Miscellaneous Commercial ServicesCommercial Services Insitut de Recherche en Immunologie et en Cancérologie develops and discovers treatment and therapies for cancers. It also engages in anticancer drug discovery chain. The company was founded in 2003 and is headquartered in Montréal, Canada. | Director/Board Member | - |
Former positions of Clarissa Desjardins
| Companies | Position | End |
|---|---|---|
| CLEMENTIA PHARMACEUTICALS INC | Founder | 2019-03-31 |
| Cepmed | Chief Executive Officer | 2011-12-31 |
La Fondation de l'innovation du Nouveau-Brunswick
 La Fondation de l'innovation du Nouveau-Brunswick Investment ManagersFinance La Fondation de l'innovation du Nouveau-Brunswick is an Independent Venture Capital firm founded in 2003. La Fondation de l'innovation du Nouveau-Brunswick is headquartered in Fredericton. | Director/Board Member | 2008-10-31 |
Caprion Pharmaceuticals, Inc.
 Caprion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Caprion Pharmaceuticals, Inc. discovered and developed pharmaceutical products. It offered a proprietary therapeutic pipeline in oncology and infectious diseases. Caprion Pharmaceuticals proteomics discovery technologies used to enable the discovery of novel targets for therapeutics development and the identification of novel protein biomarkers that can significantly enhance clinical development productivity and decision making. The company was founded in 1998 and was headquartered in Montreal, Canada. | Founder | 2006-12-31 |
Advanced Bioconcept Ltd.
 Advanced Bioconcept Ltd. Electronic Equipment/InstrumentsElectronic Technology Part of Nen Tm Life Science Products, Inc., Advanced Bioconcept Ltd. is a Canadian company that makes proprietary, fluorescent labeled peptides. The private company is based in Montréal, Canada. The company was founded by Clarissa Desjardins. Advanced Bioconcept was acquired by Nen Tm Life Science Products, Inc. on September 25, 1998. | Founder | 1997-12-31 |
Training of Clarissa Desjardins
| McGill University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| INSMED INCORPORATED | Health Technology |
| XENON PHARMACEUTICALS INC. | Health Technology |
| Private companies | 9 |
|---|---|
BELLUS Health, Inc.
 BELLUS Health, Inc. Pharmaceuticals: MajorHealth Technology BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada. | Health Technology |
Caprion Pharmaceuticals, Inc.
Caprion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Caprion Pharmaceuticals, Inc. discovered and developed pharmaceutical products. It offered a proprietary therapeutic pipeline in oncology and infectious diseases. Caprion Pharmaceuticals proteomics discovery technologies used to enable the discovery of novel targets for therapeutics development and the identification of novel protein biomarkers that can significantly enhance clinical development productivity and decision making. The company was founded in 1998 and was headquartered in Montreal, Canada. | Health Technology |
Advanced Bioconcept Ltd.
Advanced Bioconcept Ltd. Electronic Equipment/InstrumentsElectronic Technology Part of Nen Tm Life Science Products, Inc., Advanced Bioconcept Ltd. is a Canadian company that makes proprietary, fluorescent labeled peptides. The private company is based in Montréal, Canada. The company was founded by Clarissa Desjardins. Advanced Bioconcept was acquired by Nen Tm Life Science Products, Inc. on September 25, 1998. | Electronic Technology |
Genome Canada
 Genome Canada Miscellaneous Commercial ServicesCommercial Services Genome Canada provides genomic research services. It connects ideas and people across public and private sectors to find new uses for genomics, invests in large-scale science and technology to fuel innovation,and translates discoveries into applications, new technologies, societal impacts and solutions across key sectors of national importance, including health, agriculture, forestry, fisheries and aquaculture, energy, mining, and the environment. The company was founded in 2000 and is headquartered in Ottawa, Canada. | Commercial Services |
La Fondation de l'innovation du Nouveau-Brunswick
La Fondation de l'innovation du Nouveau-Brunswick Investment ManagersFinance La Fondation de l'innovation du Nouveau-Brunswick is an Independent Venture Capital firm founded in 2003. La Fondation de l'innovation du Nouveau-Brunswick is headquartered in Fredericton. | Finance |
| Cepmed | |
Insitut de Recherche en Immunologie et en Cancérologie
Insitut de Recherche en Immunologie et en Cancérologie Miscellaneous Commercial ServicesCommercial Services Insitut de Recherche en Immunologie et en Cancérologie develops and discovers treatment and therapies for cancers. It also engages in anticancer drug discovery chain. The company was founded in 2003 and is headquartered in Montréal, Canada. | Commercial Services |
Clementia Pharmaceuticals, Inc.
 Clementia Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Clementia Pharmaceuticals, Inc. provides healthcare services. It is a biopharmaceutical company, which focuses on exploiting the science of novel retinoic acid receptor gamma agonists to address bone disease and involves in development and commercialization of treatments for people living with rare diseases. Clementia Pharmaceuticals was founded by Clarissa Desjardins and Jean-Claude Tardif on November 5, 2010 and is headquartered in Montreal, Canada. | Health Technology |
Congruence Therapeutics, Inc.
Congruence Therapeutics, Inc. BiotechnologyHealth Technology Congruence Therapeutics, Inc. is a Canadian biotechnology company that operates in the field of medicine. The company was founded in 2021 by Clarissa Desjardins. Clarissa Desjardins has been the CEO since 2021. | Health Technology |
- Stock Market
- Insiders
- Clarissa Desjardins
